

UNIVERSITY OF MICHIGAN

## CLINICAL DRUG PIPELINE





Product	Company	Indication	Pre-Clinical	Phase I	Phase II	Phase III*	Marketed
Amevive	Astellas	chronic plaque psoriasis					2003
BEXXAR	GSK	non-hodgkin's lymphoma					2003
FluMist Quadrivalent	AstraZeneca	influenza vaccine					2003
Orencia	Bristol Meyers Squibb	rheumatoid arthritis					2005
Cerdelga eliglustat	Sanofi	Gaucher's disease					2014
Auryxia	Akebia	chronic kidney disease					2014
Kymriah	Novartis	leukemia, lymphoma					2017
Livtencity	Takeda Pharmaceuticals	CMV					2021
TAK-755	Takeda Pharmaceuticals	CTTP					2023
APG-2449	Ascentage Pharma	cancer				_	
Reparixin	Dompe Farmaceutici	breast cancer					
Lisaftoclax	Ascentage Pharma	cancer				_	
Ziftomenib	Kura Oncology	leukemia				_	
CLR 131	Cellectar Biosciences	leukemia, lymphoma			_		
Alrizomadlin	Ascentage Pharma	cancer					
Pelcitoclax	Ascentage Pharma	cancer & fibrosis					
APG-1387	Ascentage Pharma	hepatitis B					
ONL 1204	ONL Therapeutics	retinal, glaucoma					
TNX-1300	Tonix Pharmaceuticals	cocaine intoxication					
ESK981	Esanik Therapeutics	prostate cancer					

Product	Company	Indication	Pre-Clinical	Phase I	Phase II	Phase III*	Marketed
OpSCF antibody	Opsidio, LLC	fibrosis					
UBX-1325	Unity Biotechnology	Diabetic Macular Edema			_		
DT-678	Diapin Therapeutics	heart attack, stroke					
Orally-available PAI-1 inhibitor	MDI Therapeuitcs	fibrosis		<del></del> -			
PTM-001	PTM Therapeutics	ulcerative colitis					
PTM-001-ADC	PTM Therapeutics	colon cancers, solid tumors					
ARD-1671	Proteovant Therapeutics	cancer					
SD-436	Proteovant Therapeutics	cancer					
NNMT inhibitors	Astrazeneca	obesity, diabetes					
MTX-531	MEKanistic Therapeutics	cancer					
MTX-241F	MEKanistic Therapeutics	cancer					
miCAS-9	Genetobe, LLC	Usher syndrome, cystic fibrosis					
DPI-503	Dvant Pharma, Inc.	cancer					
ARBM-101	Arbormed Co. Ltd.	Wilson disease					
NanoDisc	EVOQ Therapeutics	celiac disease					
NanoDisc	Gilead (from EVOQ)	rheumatoid arthritis, lupus					
NanoDisc	Amgen (from EVOQ)	autoimmune disorders					
RT-10185	Resonant Therapeutics	breast, liver cancer					
DT-109	Diapin	liver disease					
LP-182	Lympharma	cancer	_				

Product	Company	Indication	Pre-Clinical	Phase I	Phase II	Phase III*	Marketed
CS-585	Cereno Scientific	cardiovascular					
TBD	Abcon Therapeutics, Inc.	mantle cell lymphoma					
TBD	Esperovax, Inc.	VLP vaccines	_				
TBD	KOR Life Sciences, LLC	cancer					
TBD	Molecure	fibrosis	_				
TBD	TenSixteen Bio	age-related diseases					
TBD	Kinesid Therapeutics	anemia	_				
TBD	HTIC	immune disorders					
TBD	Medsyn	cancer					
TBD	NuLynx	cancer					
TBD	AllinBio	rheumatoid arthritis					

\*or other "registration directed" trial. "Registration directed" refers to a clinical trial which determines whether a pharmaceuitcal is safe for human use, regardless of official denomination as a Phase III trial.